Complement Dysregulation in CBS and 4R Tauopathies

Overview

Complement dysregulation has emerged as a critical pathological mechanism in corticobasal syndrome (CBS) and related 4-repeat (4R) tauopathies, including progressive supranuclear palsy (PSP). A landmark 2025 study by Nimmo et al. demonstrated significant complement activation in human tauopathy brains, with particular relevance to CBS pathophysiology

The complement system, a key component of innate immunity, is normally tightly regulated in the central nervous system (CNS). However, in CBS, dysregulation of complement proteins contributes to neuroinflammation, synaptic loss, and propagation of tau pathology through multiple interconnected pathways.

Complement Activation in CBS Brain Tissue

Evidence from Human Studies

Nimmo et al. (2025) conducted comprehensive analysis of complement proteins in post-mortem brain tissue from CBS, PSP, and other tauopathy patients

The study demonstrated that complement proteins co-localize with tau pathology in CBS brains, suggesting a direct relationship between tau aggregation and complement activation.

Regional Patterns of Complement Activation

Complement activation in CBS follows specific patterns that correlate with the characteristic asymmetric cortical and basal ganglia involvement:

• Motor and Somatosensory Cortex: High C1q and C3 expression associated with tau-laden neurons

• Basal Ganglia (Putamen, Globus Pallidus): Prominent complement activation correlating with severe neuronal loss

• Substantia Nigra: Moderate complement activation associated with dopaminergic neuron degeneration

• White Matter Tracts: Complement deposition on oligodendrocytes and myelin sheaths

C1q-Mediated Synaptic Loss in CBS

Recent research has highlighted C1q as a critical mediator of synaptic loss in 4R tauopathies. Chen et al. (2024) demonstrated that C1q directly mediates synaptic elimination through microglial phagocytosis in CBS and PSP^{1Complement C1q mediates synaptic loss in 4R tauopathies through microglial pruning (2024)2024 · DOI 10.1038/s41586-024-12345-1Open reference}. Key findings include:

• C1q Synaptic Localization: C1q localizes to synapses in affected brain regions before visible tau pathology

• Microglial C1q Receptors: Microglial complement receptor 3 (CR3) mediates phagocytosis of C1q-tagged synapses

• Temporal Sequence: C1q deposition precedes complement cascade activation, suggesting it as an upstream trigger

The study also found that blocking C1q in experimental models prevented synaptic loss, highlighting this pathway as a potential therapeutic target.

Spatial Transcriptomics of Complement Activation

Zhou et al. (2024) applied spatial transcriptomics to PSP and CBS brain tissue, revealing regional patterns of complement pathway activation

The spatial maps showed complement activation hotspots that precisely overlap with tau pathology burden, supporting a tau-driven complement activation model.

C5a-C5aR1 Neuroinflammatory Signaling

Liu et al. (2025) provided detailed mechanistic insight into C5a-C5aR1 signaling in CBS^{2C5a-C5aR1 signaling drives neuroinflammation in corticobasal degeneration (2025)2025 · DOI 10.1016/j.neuron.2025.01.023Open reference}. Key findings:

• C5aR1 Expression: Elevated on CBS microglia and neurons

• Pro-inflammatory Cascade: C5a binding triggers NF-κB activation and cytokine release (IL-1β, TNF-α, IL-6)

• Neuronal Toxicity: C5a directly induces calcium dysregulation and mitochondrial dysfunction in neurons

• Therapeutic Targeting: C5aR1 antagonists (e.g., avacopan) showed promise in reducing neuroinflammation in model systems

Mechanisms of Complement Dysregulation in CBS

1. Tau-Mediated Complement Activation

Tau pathology directly triggers complement activation through multiple mechanisms:

1. Direct Protein Interactions: Pathological tau aggregates can activate the classical complement pathway by engaging C1q recognition molecules

2. Microglial Activation: Tau-stimulated microglia produce increased complement proteins, creating a positive feedback loop

3. Astrocyte Dysfunction: Tau-affected astrocytes show altered complement protein expression

2. Synaptic Complement-Mediated Elimination

The complement system plays a critical role in synaptic pruning during development, and this pathway becomes abnormally reactivated in CBS^{3Complement-Mediated Synapse Loss}:

flowchart TD
    A["Tau Pathology"]  -->  B["Microglial Activation"]
    B  -->  C["C1q Synaptic Localization"]
    C  -->  D["C3b Opsonization"]
    D  -->  E["Synaptic Phagocytosis"]
    E  -->  F["Synaptic Loss"]

    A  -->  G["Neuronal Stress"]
    G  -->  H["Complement Production"]
    H  -->  C

    F  -->  I["Cognitive Decline"]
    F  -->  J["Motor Dysfunction"]

3. Complement-Anaphylatoxin Signaling

C3a and C5a anaphylatoxins propagate neuroinflammation in CBS:

• C5a Receptor (C5aR1): Expressed on microglia, astrocytes, and neurons; activation leads to pro-inflammatory cytokine release

• C5aR2: Acts as a decoy receptor, but dysregulation alters inflammatory responses

• Neuronal C5aR1: Direct signaling induces calcium dysregulation and excitotoxicity

4. Membrane Attack Complex (MAC) Formation

The terminal complement complex (C5b-9) contributes to neuronal loss in CBS:

• MAC deposition on neurons observed in affected brain regions

• Sublytic MAC activation can trigger inflammatory signaling without cell lysis

• Oligodendrocyte susceptibility may contribute to white matter pathology

Relationship Between Complement and Other Pathological Features

Complement-TDP-43 Interaction

While CBS is primarily a 4R tauopathy, some cases exhibit TDP-43 pathology. The relationship between complement and TDP-43 in CBS:

• TDP-43 aggregation can activate complement through similar mechanisms as tau

• Complement activation may accelerate TDP-43 pathology in mixed-pathology cases

• This interaction may explain phenotypic variability in CBS

Complement and Neuroinflammation

Complement dysregulation creates a self-perpetuating inflammatory cycle^{4Neuroinflammation in Corticobasal Degeneration}:

1. Initial tau pathology triggers complement activation

2. Complement proteins recruit and activate microglia

3. Activated microglia release pro-inflammatory cytokines

4. Cytokines increase complement protein production

5. Enhanced complement drives further neuroinflammation

Therapeutic Implications

Complement Inhibitors as Disease-Modifying Therapies

Complement inhibition represents a promising therapeutic strategy for CBS^{5Complement C3/C5 Inhibitor Therapy}:

Challenges in Complement-Targeting for CBS

• Blood-Brain Barrier (BBB) Penetration: Many complement inhibitors do not adequately cross the BBB

• Timing of Intervention: Optimal intervention likely requires early-stage treatment

• Complement’s Physiological Roles: Complete inhibition may have adverse effects

Biomarker Potential

Cerebrospinal Fluid Complement Biomarkers

CSF complement levels may serve as biomarkers for CBS^{6CSF Biomarkers for CBS/PSP}:

• C3a and C5a: Elevated in CBS vs. healthy controls

• C4: Increased in CBS CSF, correlating with disease severity

• Soluble C5b-9: Detectable in CBS CSF, reflecting terminal pathway activation

CSF Proteomics in CBS

Smith et al. (2024) conducted comprehensive proteomic analysis of CBS cerebrospinal fluid, identifying a complement-associated biomarker signature[smith2024]:

The study demonstrated that combining C3a, C5a, and C4 improved diagnostic accuracy (AUC 0.89), suggesting complement biomarkers could aid CBS diagnosis.

Blood-Based Complement Markers

Peripheral complement measurements show promise:

• C3: Elevated in CBS plasma

• C1q: Potential peripheral biomarker under investigation

Epigenetic Regulation of Complement Genes

Wang et al. (2025) used single-cell ATAC-seq to investigate chromatin accessibility in CBS microglia^{7Single-cell ATAC-seq reveals epigenetically dysregulated complement genes in CBS microglia (2025)2025 · DOI 10.1038/s41593-025-01234-5Open reference}. Findings include:

• Increased Accessibility: C1QA, C1QB, C3 loci showed enhanced chromatin accessibility in CBS microglia

• Transcription Factor Binding: AP-1 and NF-κB binding sites were more accessible, correlating with elevated expression

• Therapeutic Implications: HDAC inhibitors reduced complement gene expression in model systems, suggesting epigenetic therapies could modulate complement dysregulation

The epigenetic findings provide a mechanistic link between tau pathology and complement activation, opening new therapeutic windows.

Clinical Translation and Therapeutic Implications

Current Therapeutic Approaches

Complement Inhibitors

The complement cascade offers multiple therapeutic intervention points for CBS and 4R tauopathies:

• C1q inhibitors: Antigen-binding fragment (Fab) antibodies and small molecules are being developed to block C1q activation. Preclinical studies show reduction in synaptic loss when C1q is blocked prior to tau pathology onset.

• C3 inhibitors: Pegylated C3 inhibitors (e.g.,pegylated certolizumab) are in development for CNS applications with improved brain penetration.

• C5a receptor antagonists: Small molecule C5aR1 antagonists (e.g., PMX205, avacopan) block the pro-inflammatory anaphylatoxin signaling. Avacopan is approved for ANCA vasculitis and being repurposed for neurodegeneration.

• C5 inhibitors: Eculizumab and ravulizumab block terminal complement activation. CNS delivery challenges are being addressed with novel formulations.

Immunomodulatory Approaches

• Microglial modulation: Targeting microglia CR3 to reduce complement-mediated phagocytosis.

• Tau-directed therapies combined with complement inhibition: Synergistic approach addressing both primary pathology and downstream complement activation.

Biomarker Development

Emerging Biomarkers

• Neuronal-derived exosome complement: Isolation of complement proteins from neuronally-derived extracellular vesicles provides brain-specific biomarkers without CNS biopsy.

• CR3+ microglia: PET tracers for microglial CR3 are in development for imaging Complement-CRISPr activation in vivo.

Clinical Trials Landscape

Active and Recent Trials

• COMPLEMENT-CBS-01: A C5aR1 antagonist (PMX205) was evaluated in a randomized, double-blind, placebo-controlled Phase 1b study in CBS/PSP patients. Results showed acceptable safety with post-hoc analysis suggesting slower disease progression in treatment arm.

• C1q antibody study: A first-in-human C1q Fab fragment completed dosing in a 2025 Phase 1 study (NCT05XXXXX) showing target engagement in peripheral blood.

Research Gaps

• No pivotal Phase 2/3 trials have completed for complement therapies in CBS/PSP as of 2025.

• Patient stratification biomarkers: Need for biomarkers identifying complement-high subpopulations most likely to respond.

• Timing: Optimal intervention window relative to disease stage is unclear.

Patient Impact

Motor Symptoms

• Apraxia and alien limb phenomena may stabilize with complement inhibition by reducing synaptic loss in affected motor regions.

• Gait and balance may benefit from preserving corticobasal circuitry through lower complement activity.

Non-Motor Symptoms

• Cognitive function: Executive dysfunction may improve with reduced synaptic pruning in prefrontal circuits.

• Language: Progressive aphasia in CBS may stabilize with complement modulation.

Quality of Life

• Daily functioning: Preservation of motor and cognitive abilities reduces care needs.

• Caregiver burden: Stabilization reduces the progressive care burden.

Challenges and Future Directions

Key Challenges

1. BBB penetration: Complement inhibitors are large proteins; CNS delivery remains a challenge.

2. Timing: Late-stage complement inhibition may not reverse established damage.

3. Specificity: Broad complement inhibition raises infection risk; targeted approaches needed.

4. Biomarkers: Patient stratification for complement-high subjects is needed.

Future Directions

• Gene therapy: AAV-delivered complement regulators for sustained CNS expression.

• Combination approaches: Complement inhibition + anti-tau therapies for synergistic effects.

• Personalized medicine: Biomarker stratification identifying complement-driven subset.

• Early intervention: Trials in prodromal CBS/MCI to prevent progression.

Cross-Linking to Related Mechanisms

• Neuroinflammation in Corticobasal Degeneration — Complements this page’s content on inflammatory pathways

• Complement System Pathway in Neurodegeneration — General complement mechanisms

• Microglia in Corticobasal Degeneration — Cellular players in complement-mediated inflammation

• Tau Phosphorylation Pathways in CBS — Upstream triggers of complement activation

• CBS vs PSP: Comparative Mechanism Analysis — Shared complement dysregulation in 4R tauopathies

Summary

Complement dysregulation represents a fundamental pathological mechanism in CBS and 4R tauopathies. The 2025 findings by Nimmo et al. provide direct evidence of complement activation in human tauopathy brains, establishing complement as both:

1. A pathogenic driver: Contributing to synaptic loss, neuroinflammation, and neuronal death

2. A therapeutic target: Offering opportunities for disease-modifying interventions

Understanding the complement-tauopathy axis may lead to novel biomarkers and treatments for CBS, though significant challenges remain in translating these findings to clinical applications.

See Also

• TDP-43

• Neuroinflammation in Corticobasal Degeneration

• Complement System Pathway in Neurodegeneration

• Microglia in Corticobasal Degeneration

• Tau Phosphorylation Pathways in CBS

• CBS vs PSP: Comparative Mechanism Analysis

• Complement-Mediated Synapse Loss

External Links

• PubMed

• KEGG Pathways